Reports Q1 revenue $8.59M vs $12.56M last year. Cash and cash equivalents were $1.8M as of March 31. Hermann Luebbert, CEO and chairman of Biofrontera Inc. (BFRI), stated, “The beginning of 2025 has been a very encouraging and rewarding period for us, as we have improved our revenues by 9%. We continue to see current customers reordering as well as new medical offices coming on board and placing their initial orders of Ameluz, illustrating the strength of our products and the success of our sales and marketing efforts. As part of our combination therapy, we also sold a good mix of the two differently-sized BF-RhodoLED lamps.”
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BFRI:
- Biofrontera Inc. announces patent protection on Ameluz until 2043
- Biofrontera Faces Nasdaq Non-Compliance Notice
- Is BFRI a Buy, Before Earnings?
- Biofrontera’s Growth Potential: Buy Rating Backed by FDA Approval and Positive Phase 3 Results
- Biofrontera Inc. Reports Record Sales and Strategic Advances